SOT 2026: Transform Your Concept Into Reality
In toxicology and drug safety, every decision you make influences timelines, risk, and patient outcomes, yet the pressure to move fast often collides with the complexity of discovery. Don’t let one moment be the deciding factor between a leading scientific breakthrough and a missed opportunity.
At the 2026 Society of Toxicology Annual Meeting, you’ll see how leading organizations are turning that challenge into an advantage by rethinking collaboration to accelerate progress without compromising rigor. Because when every moment matters, how you work and who you partner with can make all the difference.
We will be participating in poster presentations, continuing education sessions, and presenting exhibitor-hosted sessions throughout the week at this year’s SOT Annual Meeting. These sessions offer a wide range of courses that cover established knowledge and new developments in toxicology and related disciplines.
Schedule time to speak with us by completing the form on the right.
P3536: Safety Profile Assessment for IND-Enabling Studies: Bispecific Antibodies and Antibody–Drug Conjugates (ADCs)
Laura Ratcliffe, Samuel Chuang, Charles River
P4167: Aerosol Application for Prediction of Respiratory Toxicity Using a Human Airway Model
Mary McElroy, Charles River
P4726: Preclinical De-Risking of Cell Therapy Products
Shivakumar Vasanth, Benita Quist, Charles River
| P3810: Phenotypic Screening Platforms for Neurotoxicity and Neurorepair in CNS Drug Safety Assessment Mary McElroy, Peter Racz, Charles River |
| P3812: Comparative Biodistribution of an Antisense Oligonucleotide Following Intrathecal Administration Via Three Injection Techniques in Rats Chantal Voyer, Charles River |
| P4048: Antisense Oligonucleotides (ASOs) for Gene Therapy: A Retrospective Analysis of Toxicology and Safety Pharmacology Study Designs and Class Effects Clémentine Pinetre, Simon Authier, Steve Bulera, Charles River |
| P5051: Chronic Toxicity Evaluation of iPSC-Derived Neural Microtissues With Dopaminergic Neurons in RNU Nude Rats: Advancing Cell Therapy for Parkinson’s Disease Gael Quesseveur, Charles River |
Monday, March 23, 2026 | 9:15 a.m. – 10:15 a.m. (PST) | Room 23A
Driving ASO and siRNA Innovation: Key Success Factors from Discovery to Regulatory Toxicology
Speaker: Simon Authier, PhD, Principal Director, Toxicology and Veterinary Medical Services, Charles River
This session will examine critical success factors in the development of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), from discovery through regulatory toxicology. Topics include assay methodologies, study design principles, species selection, dosing strategies, and identification of key toxicological endpoints. Regulatory and modality-specific expectations, including NOAEL drivers relevant to safety assessment, will also be addressed.
Monday, March 23, 2026 | 3:15 p.m. – 4:15 a.m. (PST)
NAMs and Their (Regulatory) Applications in Safety Testing (Toxys)
Panelist: Pragati Coder, Senior Director, DART, Charles River
Wednesday, March 25, 2026 | 9:15 a.m. – 10:15 a.m. (PST) | Room 23A
Bioanalysis of Antibody Drug Conjugates by LC-MS
Speaker: Jordane Biarc, Chromatography, Charles River
Antibody–Drug Conjugates (ADCs) are a promising cancer therapy, with efficacy and safety dependent on controlled payload release. Accurate Drug-to-Antibody Ratio (DAR) measurement and kinetics are essential for understanding ADC behavior. Liquid Chromatography–Mass Spectrometry (LC–MS) offers robust quantification and characterization. Triple-quadrupole instruments monitor specific ADC fragments to calculate DAR over time, while high-resolution MS provides direct visualization of structural changes, delivering insights into ADC integrity and heterogeneity.
CE Courses
Sunday, March 22, 2026 | 1:15 p.m. - 5:00 p.m. (PST) | Ballroom 6D, Convention Center
CE-07: Lost in Translation? Navigating Species Selection for Immunotoxicological Assessment in Preclinical Studies
Presenter: Marie-Soleil Piche, PhD, Senior Scientific Director, Immunology, Charles River
Workshop
Monday, March 23, 2026 | 3:05 p.m. - 3:35 p.m. (PST) | Room 8, Convention Center
1080: Evaluation of Adversity and Selection of Dose Levels for Toxicology Studies Using Clinical Signs, Body Weight, and Food Consumption
Presenter: Manon Beekhuijzen, Head of Toxicology (DART), Charles River Laboratories
Symposium
Tuesday, March 24, 2026 | 8:30 a.m. - 8:55 a.m. (PST) | Ballroom 6D, Convention Center
1102: Endocrine-Disrupting Chemicals and the Ovary: A Pathologist’s Perspective
Presenter: Beth Dray, Scientific Director, Charles River
2025 SOT Posters
| P3021: Restrained and Unrestrained Models of Intermittent Intravenous Infusion in Mice J. D. Bultman, T. R. Gleason, and A. J. Evans, Charles River |
| P3228: NAM-Based Prediction of Respiratory Toxicity Using Human and Rat Airway Models J. Wallace, M. McElroy, Charles River |
| P3926: Incorporation of S9 Phase I and II Metabolism to Improve the Predictivity of Reporter Gene Assays for Estrogenic and Anti-androgenic Activity Using the AR and ERα CALUX Cell Lines Vera Tiggeloven, Manon Beekhuizen, Mira Wenker, and Sjoerd Verkaart, Charles River |
| P3930: Recommendations for an Alternative Testing Strategy for the S-Modality in In Vitro Endocrine Disruption Testing: Comparison of Aromatase (OPPTS 890.1200) and Steroidogenesis (OECD 456) Assay Results Joris van den Elzen, Joris van der Heijden, Wendy Koolen, Carol Stepka, Mira Wenker, and Sjoerd Verkaart, Charles River |
2025 ACT Posters
| P433: In Vitro Nonclinical Evaluation of Monoclonal Antibodies and Oligonucleotides’ Effects on Platelet Aggregation Anthony Pinçon, Frederic Kong Kaw Wa, Delphine Lourdel, Katheryne Larocque, and Florence Poitout-Belissent |
| P413: In Vitro Complement Cascade Function Assessment During Drug Development Philippe Rousseau |
| P414: Historical Data for Phototoxicity Safety Assessments—Correlations Between In Vitro Photo Safety Results and In Vivo Dermal and Ocular Phototoxic Responses Joanne Bonnerbowen |
| P205: Retrospective Evaluation of Preclinical Safety Data of Antibody Drug Conjugates (ADC) From One Charles River Laboratories Site Julie Vein, Romane Le Bouder, Frederic Gervais, and Catherine Thirion-Delalande |
| P403: An Oral (Gavage) Two-Generation Reproductive Toxicity Study of Eugenol in Rats William J. Brock, Sarah Davis, and Vinod Vijayakumar |